|
U.S. Patent No. 6,268,143: |
Automated high throughput E. coli o157:H7 PCR detection system and uses thereof |
|
U.S. Patent No. 6,258,942: |
TADG7: a novel gene expressed in ovarian tumor and uses thereof |
|
U.S. Patent No. 6,255,467: |
Human blood bacterium |
|
U.S. Patent No. 6,248,326: |
Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor |
|
U.S. Patent No. 6,245,543: |
Mutated herpes simplex virus type 1 thymidine kinases and uses thereof |
|
U.S. Patent No. 6,235,729: |
Uses of phospholipase C inhibitors |
|
U.S. Patent No. 6,232,070: |
Pharmacological targeting of mRNA cap formation |
|
U.S. Patent No. 6,217,896: |
Conjunctival inserts for topical delivery of medication or lubrication |
|
U.S. Patent No. 6,210,946: |
Modified adenovirus containing a fiber replacement protein |
|
U.S. Patent No. 6,210,923: |
Mammalian circadian regulator M-RIGUI2 (MPER2) |
|
U.S. Patent No. 6,204,026: |
Detection of M. tuberculosis complex via reverse transcriptase SDA |
|
U.S. Patent No. 6,200,810: |
Mutants of the Rb and p53 genes and uses thereof |
|
U.S. Patent No. 6,197,820: |
Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
|
U.S. Patent No. 6,194,558: |
DNA encoding human monocyte-macrophage apolipoprotein B receptor gene and protein |
|
U.S. Patent No. 6,191,290: |
Taxane derivatives for targeted therapy of cancer |
|
U.S. Patent No. 6,190,882: |
Mammalian circadian rhythm-like gene |
|
U.S. Patent No. 6,189,538: |
Tourniquet and method of using |
|
U.S. Patent No. 6,187,764: |
A and D vitamins and their metabolites: A new treatment for seasonal allergic rhinitis and atopy |
|
U.S. Patent No. 6,183,818: |
Process for ultra smooth diamond coating on metals and uses thereof |
|
U.S. Patent No. 6,177,280: |
Ricin inhibitors and methods for use thereof |
|
U.S. Patent No. 6,172,112: |
Retinoids and use thereof |
|
U.S. Patent No. 6,168,937: |
Purified .beta.1,2-xylosyltransferase and uses thereof |
|
U.S. Patent No. 6,156,727: |
Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis |
|
U.S. Patent No. 6,156,508: |
Detection of M. tuberculosis complex via reverse transcriptase SDA |
|
U.S. Patent No. 6,156,502: |
Arbitrary sequence oligonucleotide fingerprinting |
|
U.S. Patent No. 6,153,436: |
Method of gene delivery using wildtype adeno associated viral (AAV) vectors with insertions |
|
U.S. Patent No. 6,147,275: |
Corticotropin releasing factor receptor 1-deficient mice |
|
U.S. Patent No. 6,146,868: |
Glucuronoxylomannan (GXM)-O-acetylhydrolase of cryptococcus neoformans and uses thereof |
|
U.S. Patent No. 6,140,115: |
Canine .beta.-galactosidase gene and GM1-gangliosidosis |
|
U.S. Patent No. 6,136,849: |
Antibacterial and antifungal flavanones from Eysenhardtia texana |
|
U.S. Patent No. 6,136,585: |
Attenuation of negative stranded RNA viruses by rearrangement of genes and uses thereof |
|
U.S. Patent No. 6,130,313: |
Rapidly degrading GFP-fusion proteins |
|
U.S. Patent No. 6,127,523: |
Type IX collagen and fragments thereof |
|
U.S. Patent No. RE36,866: |
Anti-aids immunotoxins |
|
U.S. Patent No. 6,107,040: |
Pharmacological targeting of mRNA cap formation |
|
U.S. Patent No. 6,106,859: |
Stabilization of lipid:DNA formulations during nebulization |
|
U.S. Patent No. 6,093,808: |
I.kappa.BEGFP constructs, cell lines and methods of use |
|
U.S. Patent No. 6,090,605: |
Purified porcine kidney L-fucose kinase |
|
U.S. Patent No. 6,090,407: |
Small particle liposome aerosols for delivery of anti-cancer drugs |
|
U.S. Patent No. 6,087,398: |
Sickle cell anemia treatment |
|
U.S. Patent No. 6,074,640: |
Enhancement of tumor cell radiosensitivity using single chain intracellular antibodies |
|
U.S. Patent No. 6,043,085: |
Ehrlichia canis 120-kDa immunodominant antigenic protein and gene |
|
U.S. Patent No. 6,037,133: |
I.kappa.BEGFP constructs, cell lines and methods of use |
|
U.S. Patent No. 6,037,118: |
Viral characterization by direct detection of capsid proteins |
|
U.S. Patent No. 6,030,624: |
Mucosal immunogens for novel vaccines |
|
U.S. Patent No. 6,028,174: |
Method of diagnosing and treating gliomas |
|
U.S. Patent No. 6,028,059: |
Methods for modulating protein function in cells using intracellular antibody homologues |
|
U.S. Patent No. 6,022,879: |
Bathocuproine treatment of neurologic disease |
|
U.S. Patent No. 6,013,672: |
Agonists of metabotropic glutamate receptors and uses thereof |
|
U.S. Patent No. 6,010,894: |
Method of screening for attenuating viruses |
|
U.S. Patent No. 6,004,809: |
Calcium-independent phospholipase A.sub.2 |
|
U.S. Patent No. 6,001,329: |
Radiolabeled fusion toxins for cancer therapy |
|
U.S. Patent No. 6,001,312: |
Reactor for making uniform capsules |
|
U.S. Patent No. 5,998,150: |
Methods of measuring urinary myelin basic protein-like material |
|
U.S. Patent No. 5,997,900: |
Encapsulation system for the immunoisolation of living cells |
|
U.S. Patent No. 5,993,798: |
Oncoinhibin and methods of pharmaceutical use |
|
U.S. Patent No. 5,985,665: |
Biochemical analysis of antioxidant function of lymphocytes in culture |
|
U.S. Patent No. 5,981,728: |
Dull1 coding for a novel starch synthase and uses thereof |
|
U.S. Patent No. 5,981,705: |
Natural killer lytic associated protein |
|
U.S. Patent No. 5,981,583: |
Inhibition of nuclear transcription factor NF-.kappa.B by caffeic acid phenethyl ester (CAPE), derivatives of CAPE, capsaicin (8-methyl-N-vanillyl-6-nonenamide) and resiniferatoxin |
|
U.S. Patent No. 5,981,504: |
Genetic induction of receptors for targeted radiotherapy |
|
U.S. Patent No. 5,980,901: |
Viral defective interfering particles and uses thereof |
|
U.S. Patent No. 5,977,058; |
Antiproliferative protein from Bacillus thuringiensis var. thuringiensis |
|
U.S. Patent No. 5,976,803: |
Genetic test for equine severe combined immunodeficiency disease |
|
U.S. Patent No. 5,973,191: |
Selective inhibitors of prostaglandin endoperoxide synthase-2 |
|
U.S. Patent No. 5,972,616: |
TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas |
|
U.S. Patent No. 5,969,210: |
Methods for the characterization of compounds which stimulate STF-1 expression in pancreatic islet cells |
|
U.S. Patent No. 5,969,174: |
Competitive inhibitors of glyoxalase I and method of generating such competitive inhibitors inside tumor cells |
|
U.S. Patent No. 5,969,120: |
Mutants of the RB and P53 genes |
|
U.S. Patent No. 5,962,641: |
Method for purification of recombinant proteins |
|
U.S. Patent No. 5,962,272: |
Methods and compositions for full-length cDNA Cloning using a template-switching oligonucleotide |
|
U.S. Patent No. 5,962,271: |
Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end |
|
U.S. Patent No. 5,959,081: |
Zinc binding LIM protein S2-6 |
|
U.S. Patent No. 5,948,900: |
Streptococcus pneumoniae capsular polysaccharide genes and flanking regions |
|
U.S. Patent No. 5,948,610: |
Use of matrices comprising liquids and light absorbing particles for analysis of microorganisms by laser desorption mass spectrometry |
|
U.S. Patent No. 5,942,610: |
Non-nucleoside 1,3-diol reagents and their use to label or modify synthetic oligonucleotides |
|
U.S. Patent No. 5,939,279: |
Inhibition of bacterial binding by high-mannose oligosaccharides |
|
U.S. Patent No. 5,928,926: |
Isolation and cloning of the human ARSA-I gene and uses thereof |
|
U.S. Patent No. 5,925,802: |
Functional reconstitution of SCID-bo mice with bovine fetal hematopoietic tissues |
|
U.S. Patent No. 5,922,929: |
Thermotolerance enhancing protein |
|
U.S. Patent No. 5,914,242: |
Method for diminishing myocardial infarction using protein phosphatase inhibitors |
|
U.S. Patent No. 5,910,628: |
Cap-independent translation sequences derived from barley yellow dwarf virus |
|
U.S. Patent No. 5,910,486: |
Methods for modulating protein function in cells using, intracellular antibody homologues |
|
U.S. Patent No. 5,905,146: |
DNA binding protein S1-3 |
|
U.S. Patent No. 5,905,027: |
Method of diagnosing and treating gliomas |
|
U.S. Patent No. 5,902,583: |
Genetic induction of receptors for targeted radiotherapy |
|
U.S. Patent No. 5,895,756: |
Non-antibiotic system for selection of recombinant mycobacteria |
|
U.S. Patent No. 5,891,924: |
Curcumin (diferuloylmethane) inhibition of NF.kappa.B activation |
|
U.S. Patent No. 5,879,879: |
CIS-acting element in the human LDL receptor promoter and uses thereof |
|
U.S. Patent No. 5,872,001: |
Lanthionine antibiotic compositions and methods |
|
U.S. Patent No. 5,871,727: |
Targeted adenovirus vectors |
|
U.S. Patent No. 5,866,123: |
Gene encoding cationic amino acid transporter protein |
|
U.S. Patent No. 5,863,776: |
Method of preparing apoenzyme |
|
U.S. Patent No. 5,861,391: |
Use of dehydroepiandrosterone to treat primary adrenal insufficiency and Addison's disease |
|
U.S. Patent No. 5,856,161: |
Tumor necrosis factor receptor-I-associated protein kinase and methods for its use |
|
U.S. Patent No. 5,853,995: |
Large scale genotyping of diseases and a diagnostic test for spinocerebellar ataxia type 6 |
|
U.S. Patent No. 5,851,400: |
Method for eliminating the displacer in displacement chromatography of proteins |
|
U.S. Patent No. 5,849,493: |
Screening assay for compounds stimulating somatostatin transcription factor -1 binding to an STF-1 binding site |
|
U.S. Patent No. 5,844,001: |
Combination platinum chemotherapeutic/antiestrogen therapy for human cancers |
|
U.S. Patent No. 5,840,702: |
Cystic fibrosis treatment |
|
U.S. Patent No. 5,840,023: |
Optoacoustic imaging for medical diagnosis |
|
U.S. Patent No. 5,837,817: |
Tumor necrosis factor receptor-II-associated protein kinase and methods for its use |
|
U.S. Patent No. 5,837,543: |
Human embryo co-culture system and uses thereof |
|
U.S. Patent No. 5,831,069: |
Antisense oligonucleotides against nonstructural proteins NS1 and NS2 of respiratory syncytial virus and uses thereof |
|
U.S. Patent No. 5,824,636: |
Antiproliferative protein from Bacillus thuringiensis var. thuringiensis |
|
U.S. Patent No. 5,824,493: |
Diagnostic test for interstitial cystitis |
|
U.S. Patent No. 5,817,619: |
Protein from albus albopictus cells and method for its use |
|
U.S. Patent No. 5,817,501: |
DNA encoding suppressin protein and uses thereof |
|
U.S. Patent No. 5,814,671: |
Site selective ion exchange resins templated for lead (II) ion and methods and devices for their use |
|
U.S. Patent No. 5,798,392: |
Sulfonyl fluorides for the treatment of Alzheimer's disease |
|
U.S. Patent No. 5,789,229: |
Stranded RNA virus particles |
|
U.S. Patent No. 5,789,171: |
Use of cna, fnba, fnbb, and hlb, gene probes for the strain-specific identification of Staphylococcus aureus |
|
U.S. Patent No. 5,773,276: |
Calcium-independent phospholipase A.sub.2 |
|
U.S. Patent No. 5,773,248: |
Nucleic acid encoding a human .alpha.3(IX) collagen protein and method of producing the protein recombinantly |
|
U.S. Patent No. 5,770,430: |
Cellular injury response element and uses thereof |
|
U.S. Patent No. 5,756,479: |
Flavin adenine dinucleotide analogue inhibitors of monoamine oxidase |
|
U.S. Patent No. 5,753,483: |
Purified homogeneous UDP-GlcNAc (GalNAc) pyrophosphorylase |
|
U.S. Patent No. 5,741,673: |
Nucleic acid encoding a novel homeobox factor which stimulates insulin expression in pancreatic islet cells |
|
U.S. Patent No. 5,716,821: |
Prevention and treatment of respiratory tract disease |
|
U.S. Patent No. 5,677,277: |
Brain endothelial cell protein induced by nerve growth factor |
|
U.S. Patent No. 5,677,137: |
Method to identify immunocompromised patients at high risk for cryptococcosis |
|
U.S. Patent No. 5,674,876: |
.rho.-heteroatom-substituted phenols and uses thereof |
|
U.S. Patent No. 5,668,173: |
Method of increasing the conversion of homocysteine to methionine and uses thereof |
|
U.S. Patent No. 5,668,107: |
Compositions and methods for inhibiting elastase |
|
U.S. Patent No. 5,658,949: |
Inhibition of tumor necrosis factor by retinoic acid |
|
U.S. Patent No. 5,653,977: |
Anti-idiotypic antibody that mimics the GD2 antigen |
|
U.S. Patent No. 5,650,389: |
Methods for the inhibition of complement activation |
|
U.S. Patent No. 5,650,320: |
Lanthionine antibiotic compositions and methods |
|
U.S. Patent No. 5,650,316: |
Uses of triplex forming oligonucleotides for the treatment of human diseases |
|
U.S. Patent No. 5,645,836: |
Anti-AIDS immunotoxins |
|
U.S. Patent No. 5,643,883: |
Glucose-6-phosphate uptake inhibitors and novel uses thereof |
|
U.S. Patent No. 5,639,734: |
Disaccharide inflammation inhibitors and uses thereof |
|
U.S. Patent No. 5,631,348: |
Protein sequence of the plant toxin gelonin |
|
U.S. Patent No. 5,630,423: |
Method of measuring tissue optical properties using an optical beam of oblique incidence and uses thereof |
|
U.S. Patent No. 5,628,824: |
High growth rate homoepitaxial diamond film deposition at high temperatures by microwave plasma-assisted chemical vapor deposition |
|
U.S. Patent No. 5,626,564: |
Adjustable sideholes catheter |
|
U.S. Patent No. 5,624,827: |
DNA sequences encoding the plant toxin gelonin |
|
U.S. Patent No. 5,599,959: |
Analogues of acetylsalicylic acid and novel uses thereof |
|
U.S. Patent No. 5,594,057: |
Reversibly heat stiffening suspension |
|
U.S. Patent No. 5,593,965: |
Anti-tumor effects of GnRH-III |
|
U.S. Patent No. 5,563,173: |
Anti-proliferative effects of sodium butyrate |
|
U.S. Patent No. 5,563,153: |
Sterile topical anesthetic gel |
|
U.S. Patent No. 5,552,311: |
Purine nucleoside phosphorylase gene therapy for human malignancy |
|
U.S. Patent No. 5,532,154: |
Mutated alpha virus |
|
U.S. Patent No. 5,527,825: |
Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase |
|
U.S. Patent No. 5,523,290: |
Antiproliferation factor |
|
U.S. Patent No. 5,512,577: |
Bicyclic hexahydroaporphine and 1-benzyloctahydroisoquinoline therapeutic compositions and processes for utilizing said compositions |
|
U.S. Patent No. 5,489,612: |
Calixarene chloride-channel blockers |
|
U.S. Patent No. 5,480,142: |
Reversibly elevatable golf cup |
|
U.S. Patent No. 5,464,630: |
Liposomes that provide thymic dependent help to weak vaccine antigens |
|
U.S. Patent No. 5,457,129: |
Inhibition of nitric oxide production by retinoic acid |
|
U.S. Patent No. 5,440,017: |
T-cell lymphoma cDNA clones |
|
U.S. Patent No. 5,342,761: |
Oncofetal gene, gene product and uses therefor |
|
U.S. Patent No. 5,338,261: |
Pool cue stand and chalk holder |
|
U.S. Patent No. 5,312,733: |
Developmental marker gene of CD4-CD8 thymocytes |
|
U.S. Patent No. 5,294,446: |
Composition and method of promoting hard tissue healing |
|
|
|